Lantheus Holdings, Inc. $LNTH Shares Sold by Lido Advisors LLC

Lido Advisors LLC lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 62,205 shares of the medical equipment provider’s stock after selling 4,953 shares during the quarter. Lido Advisors LLC owned approximately 0.09% of Lantheus worth $4,140,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the second quarter worth approximately $36,000. Hantz Financial Services Inc. boosted its position in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the last quarter. Larson Financial Group LLC boosted its position in Lantheus by 324.5% during the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 503 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 230 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $100.98 on Friday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.57 billion, a P/E ratio of 24.33 and a beta of -0.03. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $104.00. The firm’s 50 day moving average is $88.01 and its two-hundred day moving average is $74.96.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter last year, the firm posted $1.53 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 4.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Truist Financial reaffirmed a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 price target on shares of Lantheus in a research note on Thursday, May 7th. Finally, JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.